Experts discuss how a global pandemic is putting pressure on traditional methods of research dissemination. A search on PubMed.gov for COVID-19 reveals 93,851 results as of Mid-January 2021.  “To put that in perspective, if I search for EGFR, a major area of cancer research, there are just over 96,000 results in the 40 years since…

In 2014 the IASLC, in collaboration with the American Thoracic Society and the European Respiratory Society, published a new classification of lung adenocarcinoma.1 The publication addressed new terminology and diagnostic criteria for lung adenocarcinoma, but it also highlighted “the importance of a close collaboration between oncologist, pathologist, molecular biologist, radiologist and surgeons …  to offer…

The COVID-19 pandemic has caused more than 43.2 million cumulative cases and 1.16 million deaths, as of late October 2020. Approximately 1% of patients with COVID-19 have malignancy,1 and lung cancer accounts for a considerable portion of these malignancies. Patients with lung cancer have often experienced severe disease when they contract COVID-19,2 which highlights the…

ILCN Editorial Group member Shirish M. Gadgeel, MD, is Chief of the Division of Hematology/Oncology at the Henry Ford Cancer Institute/Henry Ford Hospital. Dr. Gadgeel is currently working, in conjunction with four other institutions, on a phase II study evaluating pembrolizumab plus chemotherapy in patients with EGFR mutation positive and ALK translocated NSCLC previously treated…

In September 2017, the FDA approved bevacizumab-awwb for the treatment of NSCLC, with the same indications as the tradename agent. Although bevacizumab-awwb is the only biosimilar agent specific to lung cancer, there are many others in development. Gary Lyman, MD, is Professor of Public Health Sciences and Clinical Research at the Fred Hutchinson Cancer Research…

As a practicing chest radiologist in Boston, one of this article’s authors (Dr. Hatabu) encounters several patients with drug-related pneumonitis (DRP) daily when on clinical duty. Sometimes DRP coexists with COVID-19 pneumonia or radiation pneumonitis. Recently, clinicians have begun to notice the increased incidence  of DRP associated with molecular targeted therapy and immunotherapy in patients…

In Reference To: Goldberg SB, Schalper KA, Gettinger SN, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5)655-663. Many studies over the past several years have clearly demonstrated the efficacy of PD-1 and PD-L1 inhibitors for NSCLC,…

IN REFERENCE TO: Khorrami M, Jain P, Bera K, et al. Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features. Lung Cancer. 2019;135:1-9.

Although some resist its gravitational pull, social media and especially Twitter are becoming an increasingly valuable tool in academic and community-based cancer care, with thoracic oncology helping set the pace for its growing presence. As its utility continues to grow, social media has been forging a stronger international community that is no longer limited by…

With many new lung cancer treatments approved through accelerated tracks based on early-phase (I/II) trial data, we have become increasingly aware of the lack of standards for disclosing toxicities when new therapies debut at professional conferences, which may be months to a few years before they are licensed.  We collected toxicity data from all lung…